source
- Roche reports up to 30% shrinkage of chronic MS lesions with fenebrutinib, eyes FDA approvalRoche has filed for FDA approval of its BTK inhibitor fenebrutinib for both relapsing and primary progressive multiple sclerosis, after the agency accepted the submission. At the MSToronto2026 mee…
- Merck and Moderna release early phase 3 melanoma vaccine data showing primary endpoint success but weaker secondary resultsMerck and Moderna disclosed phase 3 data for their melanoma vaccine INTerpath-001 ahead of schedule after an embargo breach. The trial met its primary endpoint of recurrence‑free survival, with re…Fierce Biotech · 20d agoPositive readoutNeutral